



Drug Development and Repositioning Methodology on COVID-19

Guest Editors:

Dr. Ki Kwang Oh

Department of Bio-Health
Convergence, College of
Biomedical Science, Kangwon
National University, Chuncheon
24341, Korea

Dr. Md Adnan

Department of Bio-Health
Convergence, College of
Biomedical Science, Kangwon
National University, Chuncheon
24341, Republic of Korea

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editors

Currently, a plethora of biomedical information is available concerning COVID-19. In this context, health professionals have been challenged with finding new insights into the mechanisms underlying actions, targets, and drugs.

In particular, “drug-repurposing” is an efficient methodology that generates new therapeutics for approved drugs, but not new chemical compounds. Drug repurposing relies on data-driven approaches, such as bioinformatics, cheminformatics, and system biology, suggesting that integrated network pharmacology can elucidate the signaling pathways (mechanisms), targets, and compounds. These three components could result in a potential candidate to alleviate COVID-19.

The submission of original articles, reviews, and hypotheses is welcome. Topics of interest for this issue include, but are not limited to:

- The protein–protein interaction networks in COVID-19;
- The relationship among signaling-pathways–targets–compounds in COVID-19;
- Network pharmacology-based investigation into COVID-19;
- COVID-19 and drug treatments, either dry-based or wet-based experiment.

